Corecam Pte Ltd’s Biogen BIIB Stock Holding History

Corecam Pte Ltd’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216K	Buy	+1,000	New	+$191K	0.08%	75

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Corecam Pte Ltd's BIIB Position: Q2 2026 in Review

Corecam Pte Ltd opened a new position in Biogen (BIIB) in Q2 2026: 1,000 shares worth $216K. The stake represents 0.08% of the portfolio and ranks #75 among its holdings.

814 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Corecam Pte Ltd held 1,000 shares of Biogen worth $216K as of Q2 2026.
Biogen was a new Corecam Pte Ltd position in Q2 2026.
Biogen made up 0.08% of Corecam Pte Ltd's portfolio in Q2 2026, its #75 holding.
814 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Corecam Pte Ltd's 13F filing for Q2 2026, filed 14 Jul 2026.